Alkali
DrugOral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Other names: Bicarbonate, Citrate
NCT Number: NCT03035812
Metabolic acidosis recovers a wide range of diseases in which an oral alkalinization could be useful. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure. No prospective data has been published in clinical routine. Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. The principal criterion of evaluation will be the variation in the extracellular compartment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Centre Hospitalier Pierre Oudot - Bourgoin-Jallieu, Bourgoin, France
Metabolic acidosis recovers a wide range of diseases - chronic kidney diseases, nephrolithiasis, or others - in which an oral alkalinization could be useful. Oral alkalinization could be performed or by bicarbonate contained in alkaline-based waters or drug therapies or by citrate. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure, especially due to the amount of daily sodium load. No prospective data has been published in clinical routine, studying its effects on extracellular volume nor the blood pressure control.
Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. Initial recorded data will be: age, gender, prescription (indication, kind of alkali therapy, volume and duration), body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, comorbidities, drug therapy, blood and urine composition. The recorded follow-up will be: the adherence to treatment, body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, adverse events, blood and urine composition.
The principal criterion of evaluation will be the variation in the extracellular compartment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Other names: Bicarbonate, Citrate
Time frame: At M3 (month 3)
Evaluation of the extracellular compartment by a composite clinical outcome at M3 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on natremia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on urine output (l/d)
Time frame: At M6 (month 6)
Evaluation of the extracellular compartment by a composite clinical outcome at M6 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on kalemia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on blood chloride (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on bicarbonatemia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on proteinemia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on albuminemia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on creatininemia (mM)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on natriuresis (mmol/d)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on urine chloride (mmol/d)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on proteinuria (g/d)
Time frame: At M3 (month 3)
Evaluation of the impact of oral alkali therapy on creatinuria (mmol/d)
Jean-Philippe Bertocchio
Other
Prospective Evaluation of Oral Alkalinization by Urologists and Nephrologists: Evolution of the Extracellular Compartment
Acronym: AlcalUN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02476253
Acid-Base Imbalance, Acidosis
Montpellier, France
View Trial DetailsNCT04010630
Acid-Base Imbalance, Acidosis
Montpellier, France
View Trial DetailsNCT06908408
Acid-Base Imbalance, Acidosis
Ljubljana, Slovenia
View Trial DetailsNCT04600323
Acid-Base Imbalance, Acidosis
Aurora, Colorado, United States
View Trial Details